Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record.

Clinical development times for innovative drugs

Open access
Brown, Dean G., Wobst, Heike J., Kapoor, Abhijeet, Kenna, Leslie A., Southall, Noel · 2022 · Nature Reviews Drug Discovery

Abstract

New drug development is a race against the clock as soon as the first patents are filed, and understanding the potential timings from first-in-human studies to regulatory approval is crucial for strategic planning. Here, we use information gathered from US FDA review documents to provide insight into the timeframes of successful drug development programmes in the past decade. We define clinical development time as the number of days between the initiation of first-in-human clinical studies and regulatory marketing authorization, and we focus on the development of innovative drugs — those products that are being marketed for the first time that contain a new molecular entity or new active moiety (see Supplementary Box 1 for details of the dataset and analysis, and Supplementary Table 1 for the dataset). We also investigate how FDA regulatory programmes may affect this process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/d41573-021-00190-9

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., & Southall, N.
Venue
Nature Reviews Drug Discovery
Published
2021-11-10
Volume
21
Issue
11
Pages
793-794
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W3213042299
Cited by
173
References
0
FWCI
17.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical development times for innovative drugs. https://app.cochat.ai/papers/10.1038/d41573-021-00190-9
The paper
Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., & Southall, N. (2022). Clinical development times for innovative drugs. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-021-00190-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.